Regenxbio Inc. (NASDAQ:RGNX) is at least 72.39% than its current record low price of $16.30. There was a 4.85% gain on 11/30/2017 that led the price to move at $28.1. At recent session, the prices were hovering between $26.4053 and $28.25. This company shares are 55.98% off its target price of $43.83 and the current market capitalization stands at $876.72M. The recent change has given its price a -6.55% deficit over SMA 50 and -22.16% deficit over its 52-week high. The stock witnessed -6.18% declines, 23.52% gains and 50.27% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RGNX’s volatility during a week at 5.07% and during a month it has been found around 6.44%.Regenxbio Inc. (RGNX) Top Holders
Institutional investors currently hold around $575 million or 69% in RGNX stock. Look at its top three institutional owners. Blackrock Inc. owns $80.48 million in Regenxbio Inc., which represents roughly 9.18% of the company’s market cap and approximately 14% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 2,227,694 shares of the stock are valued at $59.7 million. The third largest holder is Redmile Group, Llc, which currently holds $44.69 million worth of this stock and that ownership represents nearly 5.1% of its market capitalization.Regenxbio Inc. 13F Filings
At the end of 09/30/2017 reporting period, 59 institutional holders increased their position in Regenxbio Inc. (NASDAQ:RGNX) by some 2,633,559 shares, 37 decreased positions by 3,842,396 and 13 held positions by 14,971,045. That puts total institutional holdings at 21,447,000 shares, according to SEC filings. The stock grabbed 23 new institutional investments totaling 1,135,074 shares while 20 institutional investors sold out their entire positions totaling 2,054,110 shares.
Multiple company employees have indulged in significant insider trading. Regenxbio Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP, Technical Operations Simpson Curran has sold 2,000 shares of Regenxbio Inc. (RGNX) in trading session dated Nov. 27, 2017. These shares are worth $58,620 and were traded at $29.31 each. The SEC filing shows that Mills Kenneth T. performed a sale of 10,000 shares. The President and CEO disposed these shares by way of transaction on Nov. 20, 2017. The company’s shares were given away at $27.71 per share worth to an income of some $277,100 on account of Mills Kenneth T..
CFO, Vasista Vittal, sold 5,000 common shares of Regenxbio Inc. (RGNX) in the open market. In a transaction dated Nov. 15, 2017, the shares were put up for sale at an average price of $25.3, raking in a sum of $126,500. After this sale, 87,283 common shares of RGNX are directly owned by the insider, with total stake valued at $2,452,652.
In the transaction dated Oct. 20, 2017, the great number of shares disposed came courtesy the President and CEO; Mills Kenneth T. disposed a total of 10,000 shares at an average price of $32.62, amounting to approximately $326,200. The insider now directly owns 98,530 shares worth $2,768,693.Regenxbio Inc. (RGNX) Analyst Guide
Several analysts have released their opinion on Regenxbio Inc. (NASDAQ:RGNX), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.25 average brokerage recommendation.